HIV does not directly cause diabetes, but living with HIV significantly raises your risk of developing type 2 diabetes. People with HIV have a diabetes prevalence of about 10.3%, and after adjusting for age, weight, and other factors, they are roughly 47% more likely to have diabetes than the general population. This elevated risk comes from a combination of the virus itself, the medications used to treat it, and the body composition changes that often accompany long-term HIV infection.
How Much Higher Is the Risk?
A study comparing HIV-positive adults to the general U.S. population found that the adjusted diabetes prevalence was 11.8% among people with HIV versus 8.0% in the general population. That gap isn’t distributed evenly. Younger adults (ages 20 to 44) with HIV were nearly three times as likely to have diabetes as their peers in the general population. Women with HIV had 68% higher odds. And people with HIV who were not obese still had an 81% higher prevalence of diabetes compared to non-obese adults without HIV.
That last point matters because it shows the increased risk isn’t simply explained by weight. Something about HIV itself, or its treatment, pushes the body toward insulin resistance even in people who wouldn’t typically be considered at risk.
What HIV Does to Blood Sugar Regulation
HIV creates a state of chronic inflammation that disrupts how your body processes sugar. The virus triggers immune cells in fat tissue to release inflammatory signals, particularly a protein called TNF-alpha and another called IL-6. These signals interfere with insulin’s ability to do its job. TNF-alpha, for example, blocks the receptor that insulin uses to tell cells to absorb sugar from the blood. It also causes the liver to release more fat into the bloodstream, which leads to excess fatty acid buildup in muscle tissue, further worsening insulin resistance.
This inflammatory process happens regardless of whether you’re taking HIV medications. The virus itself alters fat tissue, damaging fat cells and triggering a stress response that disrupts normal metabolism. Over time, this chronic low-grade inflammation makes cells less and less responsive to insulin, pushing fasting blood sugar levels upward.
HIV Medications and Diabetes Risk
Antiretroviral therapy keeps HIV under control, but some drug classes carry metabolic side effects. Older drugs like stavudine and didanosine were clearly linked to higher diabetes risk, though these are rarely prescribed today. Among more commonly used medications, regimens containing the protease inhibitor lopinavir/ritonavir and those containing efavirenz have been associated with increased diabetes risk compared to other combinations.
The newest concern involves integrase inhibitors, which are now a cornerstone of HIV treatment worldwide. These drugs have been linked to significant weight gain, especially in women. One study found that women on integrase inhibitors gained about 11% of their baseline body weight over two years, roughly 6 to 7 kilograms on average. The same study found that people on integrase inhibitors had over three times the rate of new diabetes diagnoses compared to those on other regimens, though interestingly, this increased diabetes risk did not appear to be driven by weight gain alone. Something about these drugs may independently affect blood sugar processing, though this isn’t fully understood yet.
Fat Redistribution and Metabolic Syndrome
One of the more visible effects of long-term HIV and its treatment is lipodystrophy, a condition where fat shifts from where it normally sits (arms, legs, face) to the abdomen and upper back. This pattern of losing fat in the limbs while gaining it around the organs closely mirrors metabolic syndrome, a cluster of conditions that includes high blood sugar, abnormal cholesterol, and increased cardiovascular risk.
Abdominal fat is particularly harmful because it wraps around internal organs and is far more metabolically active than fat stored under the skin. It releases more inflammatory signals and fatty acids directly into the liver, creating a feedback loop that worsens insulin resistance. HIV medications accelerate this process by increasing the breakdown of stored fat and reducing the ability of fat cells to absorb new fatty acids, flooding the bloodstream with excess lipids. The combination of fat loss in the limbs and fat gain around the belly carries metabolic consequences very similar to those seen in people with metabolic syndrome who don’t have HIV.
Hepatitis C Coinfection Adds Risk
Many people living with HIV are also coinfected with hepatitis C, and this combination further increases diabetes risk. Research has shown that hepatitis C is an independent risk factor for type 2 diabetes in HIV-positive individuals, particularly among younger, leaner patients who lack traditional diabetes risk factors like obesity or family history. In these low-risk individuals, the association between hepatitis C and diabetes was actually stronger than in people who already had conventional risk factors. This means that if you have both HIV and hepatitis C, diabetes screening is important even if you’re young and at a healthy weight.
Cardiovascular Consequences
When diabetes develops alongside HIV, the cardiovascular toll is compounded. Both HIV and diabetes independently accelerate atherosclerosis, the buildup of plaque in artery walls. Together, they create a substantially higher risk of heart attack and stroke than either condition alone. Studies of HIV-positive individuals with metabolic syndrome have found higher all-cause mortality compared to those without metabolic abnormalities, even when the virus is well controlled with medication. Managing blood sugar isn’t just about preventing diabetes complications in isolation. For people with HIV, it’s a critical part of protecting long-term heart health.
Screening and Monitoring
Clinical guidelines from organizations like the Canadian Diabetes Association list HIV as a specific risk factor that warrants earlier and more frequent diabetes screening. For most adults, screening starts at age 40, but for people living with HIV, earlier testing is recommended regardless of other risk factors. A fasting blood sugar or hemoglobin A1c test every one to three years is typical, though your doctor may test more frequently if you’re on a medication regimen known to affect metabolism, if you’ve experienced significant weight gain, or if you have hepatitis C coinfection.
Managing Diabetes With HIV
The first-line diabetes medication, metformin, is generally safe and effective for people with HIV, with one important caveat. If your HIV regimen includes dolutegravir, a widely prescribed integrase inhibitor, the dose of metformin typically needs to be reduced. Dolutegravir significantly increases how much metformin your body absorbs, which can lead to blood sugar dropping too low or to a buildup of lactic acid. Close monitoring of blood sugar is recommended when these two drugs are taken together.
Metformin can also cause digestive side effects like bloating and diarrhea, which lead roughly 30% of people with diabetes to stop taking it. For people with HIV who may already deal with gastrointestinal issues from their antiretroviral medications, this can be a real quality-of-life concern worth discussing with a provider. Older HIV drugs like stavudine and didanosine were associated with rare but serious reactions when combined with metformin, but these drugs have largely been phased out of clinical use.
Beyond medication, the standard strategies for managing blood sugar apply: regular physical activity, reducing refined carbohydrates, and maintaining a healthy weight. For people with HIV-related lipodystrophy, exercise that builds lean muscle mass can be particularly helpful, since muscle tissue is one of the primary sites where your body uses glucose.